URoutine
URoutine35
About
What does URoutine do?
URoutine is a human accountability app designed for entrepreneurs and achievers, providing human accountability buddies, groups, and networks to foster discipline, focus, and consistency without relying on motivation. It helps users build recurring habits, set daily focuses, and engage in community support to achieve their goals. The platform is trusted by over 20,000 entrepreneurs, professionals, and communities.
What is URoutine's revenue?
StartupHub estimates URoutine's annual revenue at $1.7M (range $1.6M to $1.8M, 27% confidence), based on comparable companies in the sector.
What is URoutine's valuation?
StartupHub estimates URoutine's effective valuation at $8.1M (range $5.5M to $13.2M, 18% confidence), based on comparable companies in the sector.
How much funding has URoutine raised?
URoutine has raised a total of $2M in funding. The most recent round on record is Pre-Seed.
Where is URoutine headquartered?
URoutine is headquartered in Tel Aviv, Israel.
When was URoutine founded?
URoutine was founded in 2021.
What industry does URoutine operate in?
URoutine operates in Productivity, Habit Tracking, Personal Development, Wellness, Mobile App.
Don't be a No-op
The cozy home-inventory app that helps you remember where everything is, even years later.
Something calm is taking shape.
A family operating system designed to manage household tasks, finances, and memories.
dataComet is a terminal emulator application for Macintosh computers.
Naikyuk is a platform that helps users discover and manage their digital assets and online presence.
Map your network. Track every connection. Never let a relationship go cold.
Skinnest is a platform that helps users manage and optimize their digital subscriptions and online accounts.
An entrant is a company tagged Productivity whose domain was first registered in the window, counted from registry records in the StartupHub directory. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.